Previous 10 | Next 10 |
home / stock / snnuf / snnuf news
12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL ◊ AGILI-C ◊ Cartilage Repair Implant alongside the REGENETEN ◊ Bioinductive Implant at the AAOS Annual Meeting, de...
First published randomized controlled trial for market-leading implant demonstrates impressive outcomes for rotator cuff tears Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces standout results for its REGENETEN Bioinductive Implant from a recently comp...
2023-11-05 11:11:03 ET Smith & Nephew plc (SNN) Q3 2023 Earnings Conference Call November 2, 2023, 4:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Rober...
2023-10-12 16:31:15 ET Summary Smith & Nephew's shares have fallen over 20% this summer, despite ongoing improvements in the company's operations, as ortho stocks have been especially weak. The impact of GLP-1 drugs on the knee replacement market is uncertain; reduced obesity ...
2023-08-04 02:39:09 ET Smith & Nephew plc (SNN) Q2 2023 Earnings Conference Call August 3, 2023 03:30 ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Jack Reyno...
2023-05-14 01:05:59 ET Summary Smith & Nephew has caught a 21% bid in the past 6 months despite no major fundamental changes. Long-term data analysis reveals the company's difficulty in turning capital investments into additional market valuation. Shares look to be fairly ...
Summary Smith & Nephew saw flat top-line growth, declines in earnings and CFFO relative to FY21. Management has instilled a new 12-point plan in order to drive performance from FY23 onwards. It is now a matter of execution, and we rate SNN a hold at 24x earnings, in-line with th...
Summary Smith & Nephew plc's fourth quarter results were mixed; Ortho is still lagging its rivals, but Sports Medicine & ENT and Advanced Wound Care outperformed. The company has the technology to be more competitive in ortho and gain share in major joints and extremities, but w...
Smith & Nephew plc (SNN) Q4 2022 Earnings Conference Call February 21, 2023, 03:30 AM ET Company Participants Deepak Nath - CEO Anne-Francoise Nesmes - CFO Conference Call Participants Jack Reynolds-Clark - RBC Hassan Al-Wakeel - Barclays Kyle Rose ...
Summary The Palm Valley Capital Fund invests in small cap stocks. While our Fund is new, its underlying absolute return-based investment strategy is not. We have practiced the same strategy throughout our careers in investment management. We do not believe U.S. stocks are pricing in an ...
News, Short Squeeze, Breakout and More Instantly...
Smith & Nephew Plc Ord Company Name:
SNNUF Stock Symbol:
OTCMKTS Market:
Smith & Nephew Plc Ord Website:
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal , 1 that shows a novel mechanism of actio...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative Pressure Wound Therapy System (sNPWT). NICE have rev...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing i...